Estrogen Receptors in Colorectal Cancer: Facts, Novelties and Perspectives

Abstract

Colorectal cancer (CRC) is the second cause of cancer-related death in both sexes worldwide. As pre-menopausal women are less likely to develop CRC compared to age-matched men, a protective role for estrogens has been hypothesized. Indeed, two isoforms of nuclear estrogen receptors (ER) have been described: ERα and ERβ. While the binding of 17beta-estradiol to ERα activates anti-apoptotic pathways, the interaction with ERβ activates caspase-3, inducing apoptosis. In this regard, several pieces of evidence show that ERβ tends to be under-regulated in advanced adenomas and CRC, with an opposite trend for ERα. Furthermore, ERβ stimulation slows adenomatous polyp growth and modulates relevant CRC pathways. Based on such considerations, dietary modulation of ER is promising, particularly in subjects with genetic predisposition for CRC. Nevertheless, the main limitation is the lack of clinical trials on a large population scale.

Keywords: adenoma; chemoprevention; colorectal carcinoma; estrogen receptors; estrogens; polyps.

Figure 1

Evidence from the literature shows that the stimulation of ERα leads to activation of pathways involved in cell proliferation. On the other hand, ERβ promotes cell apoptosis in colon, thus inhibiting cell replication and tumoral growth.